Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance LifesciencesBOM:543064 -0.07%87 Quick Ratio is 1.96 as of Mar. 2026, which is 1% below its 10-year median of 1.97. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 999 Drug Manufacturers companies, Cohance Lifesciences ranks better than 63.56% on this metric.
Cohance Lifesciences (BOM:543064) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cohance Lifesciences Quick Ratio Related Terms
Cohance Lifesciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cohance Lifesciences's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a Quick Ratio of 1.96 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cohance Lifesciences and its competitors. This is near median its historical median of 1.97. Over the past decade, Cohance Lifesciences' Quick Ratio has ranged from 1.08 to 8.70. According to the industry distribution chart, Cohance Lifesciences ranks #364 out of 999 companies in the Drug Manufacturers industry, placing it in the top 36.4%.
Is Cohance Lifesciences' Quick Ratio too high?
Cohance Lifesciences' current Quick Ratio of 1.96 is near median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 8.70. The Drug Manufacturers industry median Quick Ratio is 1.44. Cohance Lifesciences' value of 1.96 is 36.1% above this industry median. Based on the distribution chart, Cohance Lifesciences ranks #364 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #364 out of 999 companies for Quick Ratio. This puts Cohance Lifesciences in the upper half of its industry. The industry median Quick Ratio is 1.44. Cohance Lifesciences' value of 1.96 is 36.1% above this benchmark. Historically, Cohance Lifesciences' own Quick Ratio has ranged from 1.08 to 8.70 over the past decade. While the company's 10-year median is 1.97 vs. the industry median of 1.44, Cohance Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.44, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current Quick Ratio of 1.96 is 36.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current Quick Ratio is 1.96, which is near median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current Quick Ratio is 1.96, which is near median its 10-year median of 1.97 and 36.1% above the Drug Manufacturers industry median of 1.44. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Quick Ratio is 1.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
Quick Ratio: 1.96 (near median its 10-year median of 1.97)
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
Industry Position: 36.1% above the Drug Manufacturers median (#364 of 999)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
